Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. The company is headquartered in San Rafael California, California. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The firm has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Follow-Up Questions
Claritas Pharmaceuticals Inc のCEOは誰ですか？
Mr. Robert Farrell は Claritas Pharmaceuticals Inc の Chairman of the Board で、2016 から在籍しています。
CLAZF の株価パフォーマンスは？
CLAZF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Claritas Pharmaceuticals Inc の主な事業テーマや業界は？
Claritas Pharmaceuticals Inc は Pharmaceuticals 業界、セクターは Health Care に属しています。
